Alpha Tau Medical

Company Overview

Generating analyst summary…

Company Intelligence Q&A

What is Alpha Tau Medical's core technology?

Alpha Tau Medical's core technology is Diffusing Alpha-emitters Radiation Therapy (DaRT), which uses alpha-emitting atoms directly inserted into solid tumors to deliver a high-energy dose for focal alpha-radiation treatment.

When did Alpha Tau Medical go public?

Alpha Tau Medical went public on NASDAQ in March 2022.

Has Alpha Tau Medical received any FDA designations for its technology?

Yes, Alpha Tau Medical received FDA Breakthrough Device Designation for Alpha DaRT for the treatment of patients with SCC of the skin or oral cavity without curative standard of care, and later for the treatment of recurrent Glioblastoma Multiforme (GBM).

What was a recent clinical milestone for Alpha Tau Medical?

In May 2026, Alpha Tau Medical completed patient enrollment in its U.S. pivotal skin cancer study, advancing towards FDA approval of Alpha DaRT® for recurrent cutaneous squamous cell carcinoma.

What was a recent strategic partnership for Alpha Tau Medical?

In April 2025, Alpha Tau Medical announced an investment and strategic collaboration with Oramed Pharmaceuticals.